This page contains brief information about trametinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Trametinib is approved to be used alone or with dabrafenib to treat:
- Anaplastic thyroid cancer in patients whose disease is locally advanced or has metastasized (spread to other parts of the body) and who cannot receive local treatment. It is used with dabrafenib.
- Melanoma. It is used:
- With dabrafenib in patients who have had surgery to remove cancer that has spread to the lymph nodes.
- Alone or with dabrafenib in patients whose cancer cannot be removed by surgery or has metastasized.
- Non-small cell lung cancer that has metastasized. It is used with dabrafenib.
Trametinib is used only in patients whose cancer has a certain mutation in the BRAF gene.
Trametinib is also being studied in the treatment of other types of cancer.
More About Trametinib
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
MedlinePlus Information on Trametinib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.